@article{oai:repo.qst.go.jp:00046730,
 author = {Hisada, Yohei and Yasunaga, Masahiro and Hanaoka, Shingo and Saijo, Shinji and Sugino, Takashi and Tsuji, Atsushi and Saga, Tsuneo and Tsumoto, Kouhei and Manabe, Shino and Kuroda, Jun-ichiro and Kuratsu, Jun-ichi and Matsumura, Yasuhiro and 安永 正浩 and 辻 厚至 and 佐賀 恒夫},
 journal = {Scientific Reports (Online Only URL:http://www.nature.com/srep/index.html)},
 month = {Sep},
 note = {Despite the pathological importance of fibrin clot formation, little is known about the structure of these clots because X-ray and nuclear magnetic resonance (NMR) analyses are not applicable to insoluble proteins. In contrast to previously reported anti-fibrin monoclonal antibodies (mAbs), our anti-fibrin clot mAb (clone 102–10) recognises an uncovered region that is exposed only when a fibrin clot forms. The epitope of the 102–10 mAb was mapped to a hydrophobic region on the Bβ chain that interacted closely with a counterpart region on the γ chain in a soluble state. New anti-Bβ and anti-γ mAbs specific to peptides lining the discovered region appeared to bind exclusively to fibrin clots. Furthermore, the radiolabelled 102–10 mAb selectively accumulated in mouse spontaneous tumours, and immunohistochemistry using this mAb revealed greater fibrin deposition in World Health Organization (WHO) grade 4 glioma than in lower-grade gliomas. Because erosive tumours are apt to cause micro-haemorrhages, even early asymptomatic tumours detected with a radiolabelled 102-10 mAb may be aggressively malignant.},
 title = {Discovery of an uncovered region in fibrin clots and its clinical significance},
 year = {2013}
}